Intracervical Foley catheter with and without oxytocin for labor induction with Bishop score ≤3: a secondary analysis

What Was Tested

Researchers studied Oxytocin in this randomized controlled trial publication.

Who Took Part

PubMed tags the participants as women only.

This was a secondary analysis of a randomized, multicenter trial of patients with a live singleton pregnancy at ≥24 weeks' gestation undergoing labor induction with a Foley catheter and a Bishop score of <6.

This analysis included patients with a Bishop score of ≤3.

How the Study Was Run

The design is described as randomized and multicenter.

Because people in this Oxytocin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Running at several centres spread the Oxytocin study over different clinics and patient groups.

Exclusions included >1 cesarean delivery, unexplained bleeding, nonreassuring fetal tracing, major fetal anomalies, or other contraindications for vaginal delivery.

The subjects were randomized to receive an intracervical Foley catheter only or with concurrent oxytocin infusion.

The primary outcome for this analysis was the time from induction to delivery.

Secondary outcomes included delivery at ≤12 hours, time to delivery ≤24 hours, cesarean delivery, total time of oxytocin infusion, need for additional ripening agents, postpartum hemorrhage, chorioamnionitis, and neonatal intensive care unit admission.

What Was Measured

Topics PubMed links to this paper include Catheters, Cervical Ripening, Labor, Induced, Oxytocics, Oxytocin and Urinary Catheterization.

Author keywords: dilation and unfavorable.

What This Means in Plain Language

The paper is a randomized and multicenter study of Oxytocin.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (American journal of obstetrics & gynecology MFM), a journal based in United States.

More context: the Oxytocin compound page, all human trials.